AKVANO®-based Acne treatment
Acne vulgaris
Pre-clinical/Phase 1Active
Key Facts
About Lipidor
Lipidor is a private, pre-revenue biotech firm leveraging its AKVANO® technology platform to reformulate drugs with poor solubility and create novel topical treatments. The company's most advanced program targets psoriasis and is in Phase III clinical development, positioning it as a near-term value driver. With a lean operational model, Lipidor aims to out-license its formulations to larger pharmaceutical partners for commercialization. The company's success hinges on clinical validation of its platform and securing strategic partnerships for its pipeline assets.
View full company profileTherapeutic Areas
Other Acne vulgaris Drugs
| Drug | Company | Phase |
|---|---|---|
| Encube-002 | Encube Ethicals | Preclinical |
| Pipeline Program | MatriSys Bioscience | Preclinical |
| Acne & Impure Skin | Pelpharma Handels | Commercial |
| GM-503 | Galderma Group | Phase 1 |
| CB-03-01 (Cortexolone 17α-propionate) | Cosmo Pharmaceuticals | Phase III |
| TWYNEO® (tretinoin/BPO) | Sol-Gel Technologies | Commercial |
| SGT-510 | Sol-Gel Technologies | Phase 2 |
| TWYNEO® | Mayne Pharma Group | Marketed |
| TVB-3567 | Sagimet Biosciences | Phase 1 |